salvage therapy

Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients

Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US. The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent. The granting of orphan status could shorten …

Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients Read More »

FDA approved Jak inhibitors and their potential use in HIV – Interview with Dr Raymond Schinazi

As part of my work as a cure and salvage treatment activist, I am constantly searching for treatment options that could serve two purposes: existing medications that could help patients with multidrug resistance and at the same time be used as an approach to cure HIV.  Since my non profit (Program for Wellness Restoration) has …

FDA approved Jak inhibitors and their potential use in HIV – Interview with Dr Raymond Schinazi Read More »

New HIV Drugs in the Pipeline – 2012

Gilead has completed and released 48-week data from ongoing phase 3 studies of a four-drug fixed dose combination (elvitegravir, cobicistat, tenofovir, and FTC- called QUAD), as it has with studies of the integrase inhibitor elvitegravir and the pharmacokinetic booster cobicistat.  QUAD  will likely be approved for treatment naive patients after August this year.  Results from …

New HIV Drugs in the Pipeline – 2012 Read More »

Is There a Future for HIV-Infected Patients in “Deep Salvage”?

Print this page    •   Back to Web version of article By Nelson Vergel, B.S.Ch.E., M.B.A. May 3, 2011 “Only patients who do not take their medications as prescribed have multidrug resistance.” “Deep salvage patients no longer exist. The ones in that situation are already dead or have responded to the latest HIV antiretrovirals.” “Even if we give …

Is There a Future for HIV-Infected Patients in “Deep Salvage”? Read More »